Search
Elagolix
go.drugbank.com/drugs/DB11979ApprovedInvestigationalElagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Adm...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsPonesimod
go.drugbank.com/drugs/DB12016ApprovedInvestigationalPonesimod is a selective sphingosine 1-phosphate receptor 1 modulator indicated in the treatment of relapsing forms of multiple sclerosis in adults. Ponesimod was developed out of a need for a more selective modulator of sphingosine 1-ph...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLorvotuzumab mertansine
go.drugbank.com/drugs/DB12089InvestigationalLorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsLorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA...
Categories: P-glycoprotein inducers, Cytochrome P-450 SubstratesGepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigationalGepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV. Its target is similar to that of fluoroquinolone antibacterials - e.g. ciprofloxacin - while being structurally and p...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesGilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigationalGilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesSecoisolariciresinol
go.drugbank.com/drugs/DB12179InvestigationalSecoisolariciresinol has been used in trials studying the prevention of Breast Cancer.
Categories: P-glycoprotein inhibitorsGepirone
go.drugbank.com/drugs/DB12184ApprovedGepirone, an azapirone, is a pharmacologic analog of buspirone that acts selectively on the pre- and post-synaptic 5HT1A receptors. Although earlier clinical trials showed promising results for gepirone, its formulation as an immediate-r...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCapivasertib
go.drugbank.com/drugs/DB12218ApprovedInvestigationalHormone receptor (HR) positive, especially estrogen receptor-positive, HER2-negative breast cancer is the most common subtype of metastatic breast cancer, resulting in more than 400,000 deaths annually. Although endocrine-based therapy i...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBexagliflozin
go.drugbank.com/drugs/DB12236ApprovedInvestigationalBexagliflozin is a highly specific and potent sodium-glucose co-transporter 2 (SGLT2) inhibitor. Similar to other SGLT2 inhibitors, bexagliflozin contains three basic moieties: glucose, two benzene rings and a methylene bridge. SGLT2 is ...
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates